Niagen Bioscience (NAGE) EBIT (2010 - 2026)
Niagen Bioscience (NAGE) posted quarterly EBIT of $1.6 million for Q1 2026, down 66.97% year-over-year from $4.8 million in Q1 2025, and down 61.43% quarter-over-quarter from $4.1 million in Q4 2025.
Niagen Bioscience (NAGE) EBIT (2010 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has reported EBIT for 17 consecutive years, with $1.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBIT fell 66.97% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at $13.1 million (down 1.1% YoY), while the FY2025 annual figure was $16.3 million, up 110.7% from the prior year.
- EBIT fell to $1.6 million in Q1 2026 per NAGE's latest filing, from $4.1 million in the prior quarter.
- Across five years, EBIT topped out at $7.1 million in Q4 2024 and bottomed at -$7.7 million in Q1 2022.
- Historically, EBIT has averaged $79647.1 across 5 years, with a median of -$256000.0 in 2024.
- Annual changes were most pronounced in 2024 — EBIT jumped 4332.74% — and 2026, when it plunged 66.97%.
- Niagen Bioscience's EBIT stood at -$1.4 million in 2022, then soared by 88.37% to -$168000.0 in 2023, then surged by 4332.74% to $7.1 million in 2024, then plunged by 42.54% to $4.1 million in 2025, then slumped by 61.43% to $1.6 million in 2026.
- Business Quant data shows NAGE's EBIT at $1.6 million in Q1 2026, $4.1 million in Q4 2025, and $4.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Niagen Bioscience | 238.30 Mn | 171.56 Mn | 19.31 Mn | 700,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 700,000.00 |
| Mar 31, 2026 | 1.58 Mn |
| Dec 31, 2025 | 4.09 Mn |
| Sep 30, 2025 | 4.24 Mn |
| Jun 30, 2025 | 3.19 Mn |
| Mar 31, 2025 | 4.77 Mn |
| Dec 31, 2024 | 7.11 Mn |
| Sep 30, 2024 | 1.60 Mn |
| Jun 30, 2024 | -256,000.00 |
| Mar 31, 2024 | -731,000.00 |
| Dec 31, 2023 | -168,000.00 |
| Sep 30, 2023 | -1.15 Mn |
| Jun 30, 2023 | -2.32 Mn |
| Mar 31, 2023 | -1.97 Mn |
| Dec 31, 2022 | -1.44 Mn |
| Sep 30, 2022 | -3.07 Mn |
| Jun 30, 2022 | -6.39 Mn |
| Mar 31, 2022 | -7.73 Mn |
| Dec 31, 2021 | -5.32 Mn |
| Sep 30, 2021 | -8.84 Mn |